%0 Journal Article
%T Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial
%A Alexandra von Au
%A Andre Hennigs
%A Andreas Schneeweiss
%A Christof Sohn
%A Christoph Domschke
%A Eva Milloth
%A Florian Schuetz
%A Ingo Diel
%A Joachim Rom
%A Joerg Heil
%A Markus Wallwiener
%A Michael Golatta
%A Stefan Stefanovic
%J Archive of "OncoTargets and therapy".
%D 2016
%R 10.2147/OTT.S103130
%X Patients with metastasized breast cancer often suffer from discomfort caused by metastatic bone disease. Thus, osteoprotection is an important part of therapy in breast cancer metastasized to bone, and bisphosphonates (BPs) are a major therapeutic option. In this study, our objectives were to compare the side effects of oral versus intravenous BP treatment and to assess their clinical effectiveness
%K metastatic bone disease
%K bisphosphonates
%K adverse effects
%K clinical effectiveness
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944913/